Why Is Imunon Stock Moving Today?
Imunon signed a Cooperative Research and Development Agreement with the National Cancer Institute for its IL-12 immunotherapy IMNN-001. The stock jumped 4.878% in the first minute after the 09:30 ET announcement and was 0.665% below its pre-announcement price ten minutes later.
- Imunon entered a Cooperative Research and Development Agreement with the National Cancer Institute to develop IMNN-001, its DNA-based IL-12 immunotherapy, in new solid tumors and combinations.
- The stock traded from $1.64 to $1.72 in the first minute after the 09:30 ET announcement, a 4.878% rise on 83,810 shares.
- Ten minutes later it was at $1.6291, 0.665% below where it started.
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| IMNN | 1.64 | 1.64 | 1.72 | — | +4.88% | — |
Imunon stock is moving because the company announced a research agreement with the National Cancer Institute at 09:30 ET on September 10, 2026. The shares went from $1.64 to $1.72 in the first minute, a 4.878% rise on 83,810 shares, and then gave all of it back: ten minutes later they traded at $1.6291, 0.665% below where they started.
What Imunon announced
Imunon entered a Cooperative Research and Development Agreement, known as a CRADA, with the National Cancer Institute for IMNN-001. A CRADA is a formal partnership in which a federal lab contributes research and a company contributes its product, without the government buying the company's drug.
- The NCI's Cancer Therapy Evaluation Program takes on regulatory sponsorship of the work under its Experimental Therapeutics program.
- NCI investigators will evaluate IMNN-001 in new solid tumor indications and in combination regimens, building on Imunon's ovarian cancer data.
- Imunon keeps ownership of its background intellectual property.
- IMNN-001 is the first gene-based immunotherapy the NCI program has selected for this kind of partnered development.
IMNN-001 is a DNA-based therapy that delivers the gene for interleukin-12, a signaling protein that switches on the immune response against tumors.
How the stock traded
| Time (ET) | Price | Change from before |
|---|---|---|
| Before 09:30 | $1.64 | — |
| 09:31 | $1.72 | +4.878% |
| 09:40 | $1.6291 | -0.665% |
Why the jump faded
The announcement landed at the opening bell, when a small-cap stock's first trades often overshoot in both directions. A CRADA brings NCI resources and credibility, but it does not bring cash, a licensing fee or new clinical results, so the news changes Imunon's development path more than its near-term finances. The first minute priced the headline; the next nine minutes priced what it does not include.
The next scheduled update is Imunon's R&D Day on September 23, 2026, which the company has set aside for IMNN-001 clinical progress.
Why is Imunon stock moving today?
Imunon announced at 09:30 ET a Cooperative Research and Development Agreement with the National Cancer Institute for IMNN-001. The stock rose 4.878% in the first minute, then fell back to 0.665% below its starting price within ten minutes.
What does the NCI agreement mean for IMNN-001?
NCI's Cancer Therapy Evaluation Program takes on regulatory sponsorship, and NCI investigators will test IMNN-001 in new solid tumors and combination regimens, building on Imunon's ovarian cancer program. Imunon keeps its background intellectual property.
What is IMNN-001?
IMNN-001 is Imunon's DNA-based immunotherapy that delivers the gene for interleukin-12, a signaling protein that activates the immune system against tumors. It is in clinical development for ovarian cancer.
Sources
-
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
— GlobeNewswire
Imunon entered a CRADA with the NCI; NCI's Cancer Therapy Evaluation Program assumes regulatory sponsorship and NCI investigators will evaluate IMNN-001 in new solid tumor indications and combination regimens; Imunon retains its background intellectual property.
-
IMUNON Enters NCI Agreement for IMNN-001 Development
— StockTitan
IMNN-001 is the first gene-based immunotherapy selected by NCI/CTEP for partnered clinical development under a CRADA.
-
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
— GlobeNewswire
Imunon scheduled an R&D Day for September 23, 2026 focused on IMNN-001 clinical progress.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes recorded price reactions, search, watchlists, alerts and research tools.
Start Pro Watch live headlines -- free